oxaliplatin / Generic mfg. 
Welcome,         Profile    Billing    Logout  

1709 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT05476432: HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Recruiting
3
300
RoW
HAIC, FOLFOX 2d, FOLFOX 1d
Sun Yat-sen University, Guangzhou No.12 People's Hospital, First People's Hospital of Foshan
Hepatocellular Carcinoma
07/25
10/26
AFFORD, NCT05427669: Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer

Not yet recruiting
3
340
NA
mFOLFOXIRI, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, mFOLFOX6
Yanhong Deng
Colorectal Cancer
07/25
07/27
NCT04961970: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Recruiting
3
188
RoW
oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin
Shi Ming
Intrahepatic Cholangiocarcinoma
07/25
07/25
NCT05914610: Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Not yet recruiting
3
100
NA
Envolimab, Fruquintinib, Oxaliplatin, Tegafur
Fujian Medical University
Gastric Cancer
07/25
07/28
JCOG1801, NCT04288999: Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Recruiting
3
110
Japan
Chemotherapy, CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV, Preoperative radiotherapy, Capecitabine plus radiotherapy, Procedure, Surgery
National Cancer Center Hospital East, Japan Clinical Oncology Group, Japan Agency for Medical Research and Development
Rectal Cancer Recurrent
08/25
10/28
FORTITUDE-101, NCT05052801 / 2021-003461-35: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Active, not recruiting
3
516
Europe, Canada, Japan, US, RoW
Bemarituzumab, mFOLFOX6, Placebo
Amgen, Zai Lab (China only)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting
3
348
Europe
Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI
Federation Francophone de Cancerologie Digestive
Colorectal Neoplasms
09/25
09/27
NCT03671252: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation

Recruiting
3
776
RoW
FOLFOXIRI, XELOX, Chemoradiotherapy, TME operation, efficacy evaluation
Sun Yat-sen University
Rectal Cancer
09/25
09/28
NCT06093425: Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Not yet recruiting
3
950
NA
TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), TST001 and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin and Nivolumab, Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), Placebo and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin
Suzhou Transcenta Therapeutics Co., Ltd.
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer
10/25
01/26
NCT06097416: Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer

Not yet recruiting
3
100
NA
Neoadjuvant Chemoradiotherapy, NACRT, Total Neoadjuvant Therapy, TNT
St. James's Hospital, Ireland
Rectal Cancer
10/25
10/30
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
10/25
10/28
EFFIPEC, NCT04861558 / 2020-005210-18: Efficacy of Hyperthermic Intraperitoneal Chemotherapy

Recruiting
3
356
Europe
5Fluorouracil, Fluorouracil Accord, Fluorouracil Tevo, Irinotecan, Irinotecan Accord, Irinotecan Actavis, Irinotecan Fresenius Kabi, Oxaliplatin, Oxaliplatin Accord, Oxaliplatin Teva, Oxaliplatin Fresenius Kabi
Uppsala University
Colorectal Cancer, Peritoneal Metastases
12/25
12/29
iMAGINE, NCT04488159: Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer

Not yet recruiting
3
1638
Europe
Capecitabine, Oxaliplatin, Fluorouracil, Leucovorin, Immunoscore® assay, Physical exercise
Johannes Laengle, MD, PhD
Colon Cancer Stage III
12/25
06/26
LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/)

Hourglass Jan 2022 - Jan 2022 : Data from LEAP trial in combination with Keytruda for esophageal squamous cell carcinoma at ASCO-GI 2022
Recruiting
3
862
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL®
Merck Sharp & Dohme LLC, Eisai Inc.
Metastatic Esophageal Squamous Cell Carcinoma
12/25
12/25
NCT05244642: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Recruiting
3
60
RoW
Penpulimab, AK105, Investigator's choice of Chemotherapy
Akeso, Beijing Cancer Hospital
Hodgkin Disease Lymphoma
12/25
03/26
BALLAD, NCT04257461: A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Recruiting
3
30
Europe
Fluoropyrimidine, Capecitabine, LV5FU2, Oxaliplatin, Xeloda
Belgian Group of Digestive Oncology, Kom Op Tegen Kanker, Cancer Research UK
Small Bowel Adenocarcinoma
12/25
12/25
NCT05669092: A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Recruiting
3
174
RoW
Toripalimab, PD-1inhibitor, CRT, LCRT, SCRT, short-course radiotherapy, XELIRI, Capecitabine and Irinotecan, FOLFRINOX, Irinotecan,Oxaliplatin and 5-FU
Zhejiang Cancer Hospital
Toripalimab, Radiation
12/25
12/25
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting
3
352
Canada, US
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
01/26
11/30
NCT05198609: Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Recruiting
3
214
RoW
FOLFOX-HAIC, Camrelizumab, Apatinib
Sun Yat-sen University
Hepatocellular Carcinoma
01/26
01/26
NCT05701436: Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Recruiting
3
144
RoW
Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed
Zhujiang Hospital
Liver, Cancer of, Primary Resectable
01/26
03/26
NCT05766605: Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Recruiting
3
90
RoW
Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed
Zhujiang Hospital
Hepatocellular Carcinoma Resectable
01/26
01/26
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Recruiting
3
176
RoW
Experimental drug, CAP, Control Rx, FOLFIRI+BEV
Sun Yat-sen University
Metastatic Microsatellite-stable Colorectal Cancer
01/26
01/27
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruiting
3
190
RoW
HX008, Investigator's Choice Chemotherapy
Taizhou Hanzhong biomedical co. LTD
Metastatic Colorectal Cancer
01/26
10/28
RENAISSANCE, NCT02578368 / 2014-002665-30: Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Active, not recruiting
3
183
Europe
5-Fluorouracil, 5-FU, Leucovorin, calcium folinate, Oxaliplatin, Docetaxel, Trastuzumab, sodium folinate, Surgery
Krankenhaus Nordwest, German Research Foundation, Arbeitsgemeinschaft fur Internistische Onkologie
Gastric Cancer
02/26
02/26
PREOPANC-3, NCT04927780: Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Recruiting
3
378
Europe
Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Oxaliplatin, Resection
Erasmus Medical Center, Dutch Pancreatic Cancer Group, Dutch Cancer Society
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
02/26
07/29
LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/)

Active, not recruiting
3
890
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU
Merck Sharp & Dohme LLC, Eisai Inc.
Advanced/Metastatic Gastroesophageal Adenocarcinoma
02/26
02/26
NCT05263219: DEB-TACE+HAIC vs. HAIC for Large HCC

Recruiting
3
230
RoW
dTACE-HAIC, HAIC, dTACE-HAIC protocol, Drugs for DEB-TACE and HAIC, HAIC protocol, Drugs for HAIC
Second Affiliated Hospital of Guangzhou Medical University, Hainan General Hospital, Maoming People's Hospital, Zhongshan People's Hospital, Guangdong, China, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan, Jiangmen Central Hospital, First Affiliated Hospital, Sun Yat-Sen University
Unresectable Hepatocellular Carcinoma
02/26
02/26
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Recruiting
3
680
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
03/26
07/28
TOURMALINE, NCT05771480: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Recruiting
3
140
Europe, Japan, US, RoW
Durvalumab, Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union., Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Background gemcitabine-based chemotherapy Regimen
AstraZeneca
Biliary Tract Cancer
09/25
03/26
GASTRICHIP, NCT01882933: D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma

Active, not recruiting
3
367
Europe
HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin, Curative gastrectomy
Hospices Civils de Lyon
Gastric Adenocarcinoma
05/26
05/26
NCT05236972: PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Recruiting
3
323
RoW
Sintilimab, Oxaliplatin, capecitabine
Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, West China Hospital
Colorectal Carcinoma
06/26
12/28
TACTIC, NCT05593458: Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1

Recruiting
3
190
RoW
Oxaliplatin by arterial infusion plus S-1, SOX neoadjuvant, Sintilimab neoadjuvant, gastrectomy plus D2 lymph node dissection, SOX adjuvant, Sequential S-1, Sintilimab adjuvant
Zhejiang University
Locally Advanced Gastric Carcinoma
06/26
12/26
NCT05948072: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Not yet recruiting
3
250
RoW
mFOLFOX6 + Cetuximab, mFOLFOX 6
Fudan University
Colorectal Cancer, Liver Metastases
07/26
07/26
STAR-221, NCT05568095: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Active, not recruiting
3
1040
Europe, Canada, Japan, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Arcus Biosciences, Inc., Gilead Sciences, Taiho Pharmaceutical Co., Ltd.
Advanced Upper Gastrointestinal Tract Adenocarcinoma
05/26
05/26
CAREME, NCT05699746: CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD

Not yet recruiting
3
38
RoW
Capecitabine tablets, Oxaliplatin
Zhejiang University, GeneCast Biotechnology Co., Ltd.
Colorectal Cancer
09/26
12/26
NCT04460352: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting
3
1020
Europe, Canada
Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Neoadjuvant chemotherapy, Esophagectomy, Neoadjuvant radiotherapy (arm B), Neoadjuvant Platin-Taxane Regimen (alternative 1), Cisplatin, paclitaxel, Platinum-Fluoropyrimidine Regimens (alternative 2a), Oxaliplatin, calcium folinate, 5-fluorouracil, Platinum-Fluoropyrimidine Regimens (alternative 2b)
Karolinska University Hospital, University of Leipzig, The Swedish Research Council
Esophageal Squamous Cell Carcinoma
09/26
12/31
FORTITUDE-102, NCT05111626 / 2021-003477-61: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer

Recruiting
3
528
Europe, Canada, Japan, US, RoW
Bemarituzumab, AMG 552, Nivolumab, Chemotherapy, Placebo
Amgen
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
09/26
09/26
PERISCOPE II, NCT03348150 / 2015-005695-15: Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.

Recruiting
3
182
Europe
Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), HIPEC
The Netherlands Cancer Institute, Erasmus Medical Center, UMC Utrecht, University Medical Center Groningen, Catharina Ziekenhuis Eindhoven
Stomach Neoplasm, Peritoneal Carcinomatosis
10/26
10/29
PREVENT, NCT04447352: HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ

Recruiting
3
200
Europe
5-Fluorouracil, 5-FU, Leucovorin, Calciumfolinat, Oxaliplatin, Docetaxel, Cisplatin
Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
11/26
05/27
MK-3475-C66, NCT05239741: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer

Recruiting
3
100
RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Oxaliplatin, Leucovorin, 5-fluorouracil, 5-FU, Irinotecan, Bevacizumab, Cetuximab
Merck Sharp & Dohme LLC
Colorectal Neoplasms
11/26
11/26
NCT03368651: The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Recruiting
3
230
RoW
TAI
Sun Yat-sen University
Hepatocellular Carcinoma
11/26
12/28
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting
3
540
RoW
Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab
Sun Yat-sen University
Gastric Cancer
12/26
12/28
NORAD01, NCT03875781: Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer

Recruiting
3
540
Europe
Chemotherapy, Radiochemotherapy
Assistance Publique - Hôpitaux de Paris
Rectal Cancer, Advanced Cancer
12/26
12/26
NRG-GI006, NCT03801876: Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Recruiting
3
300
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Esophagectomy, excision of the esophagus, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Proton Beam Radiation Therapy, PBRT, Proton Radiation Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, FOLFOX regimen, FOLFOX, CAPOX regimen, CAPE-OX, OxCap, Docetaxel, Taxotere, 5FU, 5-FU, flurouracil, Tolak, Fluoroplex, Efudex, Carac, Adrucil
NRG Oncology, National Cancer Institute (NCI)
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
12/26
12/31
NCT03426904: Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

Recruiting
3
560
RoW
Neoadjuvant FOLFOX, Conventional adjuvant FOLFOX
Kyungpook National University Hospital
Colon Cancer
12/26
12/29
RESONANCE-2 study, ChiCTR1900023293: A prospective multicenter, randomized, controlled phase III study of oxaliplatin combined with S-1(SOX) neoadjuvant chemotherapy for different cycles in patients with locally advanced gastric adenocarcinoma

Not yet recruiting
3
524
 
give SOX for 5 cycles before operation ;give SOX for 3 cycles before operation
the first Medical Center of Chinese PLA General Hospital; Chinese PLA General Hospital, self-raising
locally advanced gastric adenocarcinoma
 
 
CIRCULATE, NCT04120701: CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II

Recruiting
3
1980
Europe
mFOLFOX6
Centre Hospitalier Universitaire Dijon
Patients With Resected Stage II Colon Cancer
01/27
01/28
NCT05144854: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active, not recruiting
3
626
Japan, RoW
ONO-4538, Nivolumab, Opdivo, Ipilimumab, BMS-734016, Yervoy, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium
Ono Pharmaceutical Co. Ltd
Gastric Cancer
02/27
05/27
KEYNOTE 975, NCT04210115 / 2019-002006-51: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Calendar Jan 2026 - Dec 2026: Data from KEYNOTE-975 trial for esophageal cancer
Active, not recruiting
3
700
Europe, Canada, Japan, US, RoW
pembrolizumab, MK-3475, KEYTRUDA®, placebo, Normal saline solution, cisplatin, PLATINOL®, 5-FU, ADRUCIL®, radiotherapy, leucovorin, calcium folinate, folinic acid, levoleucovorin, FUSILEV®, calcium levofolinate, levofolinic acid, oxaliplatin, ELOXATIN®
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
02/27
02/27
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Not yet recruiting
3
480
RoW
Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin
Shanghai Junshi Bioscience Co., Ltd.
Intrahepatic Cholangiocarcinoma
05/27
05/27
NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting
3
825
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
06/27
06/27
HAIC, NCT06041477: Concurrently vs Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable HCC

Recruiting
3
540
RoW
Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Hepatic arterial infusion chemotherapy (HAIC), Concurrent Lenvatinib, Concurrent targeted therapy, Concurrent PD-1 antibody, Concurrent immunotherapy, Sequential Lenvatinib, Sequential targeted therapy, Sequential PD-1 antibody, Sequential immunotherapy
Sun Yat-sen University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan
Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
07/27
07/30
NCT04997837: Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Recruiting
3
433
RoW
PD-1 inhibitor, Oxaliplatin, Capecitabine, Tegafur-gimeracil-oteracil potassium, 5-FU, Radiotherapy, Chemotherapy
Fudan University
Gastric Cancer
07/27
10/27
ChiCTR2200062808: A Randomized Control Clinical Trial of FOLFOXIRI versus FOLFOX Neoadjuvant Therapy for High Risk Stage III Colon Cancer

Not yet recruiting
3
92
 
FOLFOXIRI regimen ;FOLFOX regimen
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, none
colon cancer
 
 
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Leucovorin, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Leucovorin, Oxaliplatin, 5-FU, Irinotecan
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
NCT05700448: Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Not yet recruiting
3
150
NA
Sugemalimab, Placebo, Pegaspargase, Gemcitabine, Oxaliplatin
CStone Pharmaceuticals
Extranodal NK/T-cell Lymphoma
11/27
11/28
TRIGGER, NCT02704520 / 2015-003009-40: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial

Recruiting
3
441
Europe
High resolution MRI scan, mrTRG assessment
Imperial College London
Rectal Cancer
12/27
12/34
NCT04375605: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Active, not recruiting
3
342
Europe
5-Fluorouracil, Calcium folinate, Folinic Acid, Oxaliplatin, Docetaxel, Radiation, Oxaliplatin during radiotherapy, 5-Fluorouracil during radiotherapy
Universitätsmedizin Mannheim, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)
Gastroesophageal Junction Adenocarcinoma
12/25
12/25
NCT01935778: Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Recruiting
3
286
RoW
Docetaxel and capecitabine and oxaliplatin, docetaxel/xeloda/oxliplatin, capecitabine and oxaliplatin
Asan Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Inha University Hospital, Hallym University Medical Center
Gastric Cancer, Adjuvant Chemotherapy, XO
06/28
06/28
TaLaR-02, NCT05984485: The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer

Recruiting
3
766
RoW
neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision
Sun Yat-sen University
Rectal Cancer
07/28
07/28
CLAUDIA, NCT05534087: Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

Recruiting
3
236
RoW
mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy
Seoul National University Hospital
Colon Cancer
09/28
09/30
A022102, NCT05677490: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting
3
382
US
Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione,, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, Calcium (6S)-Folinate, Calcium Folinate, Oxaliplatin, 1-OHP, Dacotin, Dacplat, ELOXATIN, Irinotecan, Nivolumab, MDX-1106, Opdivo, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
11/28
11/28
NCT05314998: Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Not yet recruiting
3
394
Europe
Oxaliplatin, Irinotecan, Folinic acid, 5-fluorouracil, Gemcitabine, Capecitabine
John Neoptolemos, Molecular Health GmbH, Deutsches Krebsforschungszentrum (DKFZ), Nationales Centrum für Tumorerkrankungen, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Institut für Medizinische Biometrie
Pancreatic Ductal Adenocarcinoma
01/31
09/31
NCT05797077: Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

Recruiting
3
346
RoW
Colorectal resection surgery., FOLFOX chemotherapy regimen, CapeOx chemotherapy regimen, Capecitabine, 5-FU/LV
Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related
02/29
02/31
NCT05863195: Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting
3
408
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Floxuridine, 2'-Deoxy-5-fluorouridine, 5-Fluoro-2'-deoxyuridine, 5-Fluorodeoxyuridine, 5-Fluorouracil deoxyriboside, 5-FUdR, FDUR, Floxuridin, Fluorodeoxyuridine, Fluorouridine Deoxyribose, Fluoruridine Deoxyribose, FUdR, WR-138720, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Implantation, Intrahepatic Infusion Procedure, HAI, Hepatic Arterial Infusion, Hepatic Artery Infusion, IHI, Intrahepatic Infusion, Irinotecan, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
06/29
06/34
ENSEMBLE, NCT05646511: Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer

Recruiting
3
608
Japan
SCRT, Active Comparator & Experimental, CAPOX, Active Comparator, CAPOXIRI, Experimental
National Cancer Center Hospital East, Japan Agency for Medical Research and Development
Locally Advanced Rectal Cancer
12/29
12/30
NCT05797467: Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

Recruiting
3
366
RoW
FOLFOX chemotherapy regimens, CapeOx regimens, Bevacizumab, Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Chemotherapy Effect
04/30
04/33
NCT04495088: Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Recruiting
3
818
Europe
mFOLFOX (neoadjuvant), Folinic acid, Oxaliplatin, 5-FU, XELOX (neoadjuvant), Capecitabine, Oxaliplatin, mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), Capecitabine, infusional 5-FU/FA "AIO" regimen (adjuvant), 5-FU, Folinic acid, infusional 5-FU/FA "de Gramont" (adjuvant)
Ralf Hofheinz, Deutsche Krebshilfe e.V., Bonn (Germany), Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, German Rectal Cancer Study Group
Rectal Cancer
08/30
08/30
NCT05815082: ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

Recruiting
3
490
RoW
Colorectal cancer resection combined with liver metastasis resection., FOLFOX chemotherapy regimen, CapeOx chemotherapy regimen
Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Chemotherapy Effect
02/31
02/33
ACTRN12617001566325: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC-III)

Recruiting
2/3
1000
 
Australasian Gastro-Intestinal Trials Group, Marcus Foundation
Colorectal Cancer
 
 
2006-006088-22: Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction Prospektive multizentrische Phase III-Studie zur zytoreduktiven Chirurgie mit hyperthermer intraperitonealer Chemoperfusion nach präoperativer Chemotherapie beim Magenkarzinom inkl. AEG mit primärer peritonealer Metastasierung (Gastripec I)

Ongoing
2/3
180
Europe
Epirubicin, Oxaliplatin, capecitabin, Cisplatin, Trastuzumab, Mitomycin, Solution for infusion, Concentrate for solution for infusion, Tablet, Powder for infusion
Klinik für Chirurgie, Charité Campus Virchow-Klinikum, Deutsche Krebshilfe
Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction Peritoneal metastasiertes Magenkarzinom inkl. AEG, Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction Peritoneal metastasiertes Magenkarzinom inkl. AEG, Diseases [C] - Cancer [C04]
 
 
2010-020787-37: Pre treatment with chemotherapy followed by surgery and removal of all intra-abdominal tumor and intra-peritoneal heated chemotherapy for peritoneal metastastasized colorectal cancer.

Ongoing
2/3
10
Europe
Capecitabine, Oxaliplatin, Mytomycin C, Tablet, Powder and solvent for solution for infusion, Solution for peritoneal dialysis, Capecitabine, Oxaliplatin, Mytomycin C
Universitair Medisch Centrum Groningen, University Medical Center Groningen
peritoneal carcinomatosis of colorectal origin, Peritoneal metastasized colorectal cancer, Diseases [C] - Cancer [C04]
 
 
ATTRACTION-4, NCT02746796: Study of ONO-4538 in Gastric Cancer

Checkmark From ATTRACTION-4 trial in combination with chemo in 2L gastric cancer at ESMO 2020
Sep 2020 - Sep 2020: From ATTRACTION-4 trial in combination with chemo in 2L gastric cancer at ESMO 2020
Completed
2/3
680
Japan, RoW
ONO-4538, Oxaliplatin, Tegafur- Gimeracil-Oteracil potassium, Capecitabine, Placebo
Ono Pharmaceutical Co. Ltd
Gastric Cancer
01/20
11/22
JCOG0603, UMIN000000653: Randomized study of hepatectomy+mFOLFOX6 vs. hepatectomy alone for liver metastasis of colorectal cancer

Active, not recruiting
2/3
300
Japan
oxaliplatin - Generic mfg., leucovorin calcium - Generic mfg., 5-fluorouracil - Generic mfg.
Japan Clinical Oncology Group(JCOG), Japan Agency for Medical Research and Development
Resected liver metastasis from colorectal cancer with curative intent
 
 
CheckMate 9X8, NCT03414983 / 2017-003662-27: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

Hourglass Apr 2021 - Sep 2021 : From CheckMate 9X8 trial in combination with Avastin for 1L CRC
Completed
2/3
196
Europe, Canada, Japan, US
Nivolumab, BMS-936558, Opdivo, Oxaliplatin, Leucovorin, Calcium Folinate, Fluorouracil, Bevacizumab, Avastin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Colorectal Cancer
02/21
12/22
NCT04060472: Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors

Not yet recruiting
2/3
57
NA
albumin-bound paclitaxel + oxaliplatin
Dong Wang
Advanced Hepatobiliary and Malignant Tumors
04/21
10/23
POWERRANGER, NCT01404156: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma

Recruiting
2/3
60
Canada
(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, ECF/ECX or FLOT, Carboplatin paclitaxel plus concurrent radiotherapy
Dr. Gordon Buduhan, CancerCare Manitoba, University of Toronto, London Health Sciences Centre
Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
06/21
06/22
NCT04370418: Neo-adjuvant Short Course Chemo-radiation Therapy in Locally Advanced Rectal Cancer Patients

Recruiting
2/3
8
RoW
short course chemo-radiation with 5-fluorouracil, 5-fu
Assiut University
Neo-adjuvant Short Course Chemo-radiotherapy in Locally Advanced Cancer Rectum
06/21
09/23
ACTRN12609000035224: TOP GEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer

Active, not recruiting
2/3
570
 
Australasian Gastro-Intestinal Trials Group (AGITG), Cancer Australia through The Priority-driven Collaborative Cancer Research Scheme, Cancer Council Australia, National Health and Medical Research Council
Resectable Gastric Cancer
 
 
ChiCTR2000040536: A randomized, controlled , double-blind clinical study on the prevention and treatment of peripheral neurotoxicity of oxaliplatin by Danggui Sini granule

Not yet recruiting
2/3
64
 
Oxaliplatin chemotherapy combined with simulators ;Oxaliplatin chemotherapy combined with Danggui Sini granules.
Jiangsu Province Hospital on Integration Chinese and Western Medicine; Jiangsu Province Hospital on Integration Chinese and Western Medicine, Independent Research project of Project Jiangsu Province Academy of Traditional Chinese Medicine, BM2018024-2019010
Peripheral neurotoxicity of oxaliplatin
 
 
RJGC-Senile, NCT04677673: Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients

Not yet recruiting
2/3
232
NA
Chemotherapy, Modified SOX, Curative gastrectomy
BIRENDRA KUMAR SAH
Gastric Cancer, Chemotherapy Effect, Elderly Patients, Surgery
01/22
01/27
2021-003313-18: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate the most effective dose and the safety of medication MK-2140 when combined with standard treatments in patients with Diffuse Large B-Cell Lymphoma who failed prior therapies.

Ongoing
2/3
420
Europe
Zilovertamab Vedotin, Gemcitabine hydrochloride, Bendamustine Chydrochloride, Oxaliplatin, MK-2140, Solution for injection, Powder for solution for infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Gemcitabine SUN, Bendamustin medac, Oxaliplatin AqVida, MabThera 100mg, MabThera 500 mg
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin's lymphoma, in patients who failed prior therapies), Diseases [C] - Cancer [C04]
 
 
NCT03957733: Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.

Recruiting
2/3
338
RoW
Chemotherapy, Folfox, Xelox
King Abdullah Medical City, King Faisal Specialist Hospital & Research Center, King Saud Medical City, Al Hada Military Hospital
Rectal Cancer
05/22
11/25
RESOLVE-2, NCT03691454: Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.

Active, not recruiting
2/3
258
RoW
Docetaxel, Oxaliplatin, S-1, Herceptin
Peking University
Gastric Adenocarcinoma
06/22
06/23
PUMP-IT, NCT04552093: Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy

Recruiting
2/3
31
Europe
Floxuridine, FUDR, Tricumed IP2000V infusion pump
The Netherlands Cancer Institute, Erasmus Medical Center
Colorectal Neoplasms
06/22
12/22
NCT02942706: Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

Not yet recruiting
2/3
200
NA
Cetuximab, Erbitux, mFOLFOX6, FOLFIRI
Ruijin Hospital, Chinese PLA General Hospital, Xiangya Hospital of Central South University, West China Hospital, Tongji Hospital
Colorectal Cancer
10/22
10/22
NCT04856787: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Recruiting
2/3
439
RoW
SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic Colorectal Cancer (mCRC)
11/22
11/24
ACTRN12618000335291: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study (DYNAMIC- Pancreas)

Terminated
2/3
438
 
Australasian Gastro-Intestinal Trials Group, Marcus Foundation
Pancreatic Cancer
 
 
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2/3
178
RoW
Neoadjuvant treatment
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
12/22
12/24
PROSPECT, NCT01515787: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Active, not recruiting
2/3
1194
Europe, Canada, US, RoW
FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Canadian Cancer Trials Group
Colorectal Cancer
12/22
06/24
DRAGON - IV, NCT04208347: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruiting
2/3
580
RoW
Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin, Apatinib 500mg
Ruijin Hospital
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
12/24
08/25
NCT05002686: Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

Recruiting
2/3
60
RoW
Sintilimab, IBI308, Albumin-Paclitaxel, Capecitabine, Oxaliplatin, Radiation, Radical gastric cancer surgery
Ruijin Hospital
Gastric Cancer
08/23
08/24
NCT03686254: The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Recruiting
2/3
160
RoW
RFA, bevacizumab and second-line chemotherapy, Bevacizumab and second-line chemotherapy
Nanfang Hospital of Southern Medical University
Colorectal Neoplasms Malignant
10/23
10/23
2010-018572-25: Carcinomes Oesophagiens Non opérés traités par Chimioradiothérapie à base d’Oxaliplatine (FOLFOX-4) et Radiothérapie à Dose Elevée (CONCORDE) : Essai de phase II-III

Not yet recruiting
2/3
252
Europe
Powder for solution for infusion, Solution for infusion, ELOXATINE, ELVORINE, FLUOROURACILE
Centre Georges-François Leclerc
Carcinomes oesophagiens non opérés
 
 
NCT03607656: The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer

Completed
2/3
270
RoW
Oxaliplatin, Capecitabine, TCM, S-1, Docetaxel, 5-FU
Shanghai University of Traditional Chinese Medicine, RenJi Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine
Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC
10/22
11/23
NCT05833815: Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Recruiting
2/3
56
RoW
Everolimus 10 mg, CapOx/GemOx, Standard of care, Chemotherapy
Banaras Hindu University
Gallbladder Cancer
11/23
11/23
MAHOGANY, NCT04082364: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Active, not recruiting
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
06/25
Neo-TACE, NCT05171166: Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Recruiting
2/3
156
RoW
HAIC, TACE, FOLFOX, oxaliplatin, leucovorin, 5-fluorouracil, cTACE or DEB-TACE, EPI, Donafenib, Dona
Peking University
Hepatocellular Carcinoma
06/24
12/24
RusGCG-01, NCT04393584: FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting
2/3
538
RoW
Irinotecan, 5-FU, Leucovorin, Oxaliplatin, Docetaxel
Blokhin's Russian Cancer Research Center
Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel, Oxaliplatin, Fluoruracil, Irinotecan Hydrochloride
01/24
01/26
 

Download Options